Open AccessTreatment of severe henoch-schonlein purpura nephritis with mycophenolate mofetil
Author(s) -
Ahmad Ali Nikibakhsh,
Hashem Mahmoodzadeh,
Mohamad Karamyyar,
Sasan Hejazi,
Mehran Noroozi,
A. A. Macooie
Publication year - 2014
Publication title -
saudi journal of kidney diseases and transplantation/našrat amraḍ wa zira'aẗ al-kulaẗ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 30
eISSN - 2320-3838
pISSN - 1319-2442
DOI - 10.4103/1319-2442.135182
Subject(s) - medicine , nephritis , henoch schonlein purpura , lupus nephritis , purpura (gastropod) , mycophenolate , glomerulonephritis , immunology , vasculitis , proteinuria , nephrotic syndrome , gastroenterology , nephritic syndrome , kidney , disease , transplantation , ecology , biology
Henoch-Schonlein purpura (HSP) is the most common childhood vasculitis. Renal involvement in HSP is one of the major causes of chronic renal failure in children. It is important to start effective and relatively safe medication to prevent end-stage renal disease (ESRD). Mycophenolate mofetil (MMF) appears to be a promising therapeutic agent in many autoimmune diseases such as lupus nephritis and vasculitis. Herein, we describe the treatment with MMF of three patients with HSP nephritis. In two cases with rapidly progressive glomerulonephritis without response to steroid, after treatment with MMF, significant improvement in kidney function and proteinuria were observed. In another patient with HSP nephritic-nephrotic syndrome who showed resistance to steroid, MMF offered a favorable effect. MMF seems to be a promising therapeutic agent in the treatment of the severe HSP nephritis.